Inte:Ligand participates at EU FP7 project ‘KINACEPT’
Date: Tuesday, March 3rd, 2009
Categories: Press releases, Science
The EU has confirmed funding for the EU FP7 research project KINACEPT (’Novel anti-inflammatory compounds for autoimmune diseases’), where Inte:Ligand will participate as a partner for in-silico drug discovery,
The project consortium consists of the Czech Academy of Sciences’ Molecular Genetics Institute (Czech Republic), CAIR Bioscience (Germany), Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology (Germany), Synovo GmbH (Germany), University Clinic Erlangen (Germany), University of Tubingen (Germany), Intercept SA (Italy), University of Perugia (Italy), Inte:Ligand (Austria) and the William Harvey Research Institute (UK).
Further information is available at the research headlines website of the European Commission.